Dexamethasone: A Synthetic Glucocorticoid for Inflammatory and Immune Conditions
Dexamethasone is a synthetic glucocorticoid (corticosteroid) indicated for a wide range of severe or incapacitating inflammatory, allergic, and autoimmune conditions. It works by decreasing inflammation and suppressing the normal immune response.
How Dexamethasone Works (Pharmacology)
Dexamethasone exerts its effects primarily by:
- Decreasing inflammation: It inhibits the migration of leukocytes (white blood cells) to sites of inflammation and reverses increased capillary permeability.
- Suppressing immune response: It dampens the body's normal immune reactions.
Key Indications & Benefits
Dexamethasone is indicated for numerous conditions across various body systems, often when conventional treatments are inadequate or for acute exacerbations:
- Allergic states: Severe or incapacitating allergic conditions like asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness.
- Collagen diseases: Such as lupus erythematosus and rheumatoid arthritis.
- Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome).
- Endocrine disorders: Primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with cancer, and non-suppurative thyroiditis.
- Gastrointestinal diseases: Regional enteritis and ulcerative colitis.
- Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, and selected cases of secondary thrombocytopenia.
- Neoplastic diseases: Leukemias and lymphomas.
- Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema (associated with brain tumors, craniotomy, or head injury).
- Ophthalmic diseases: Temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
- Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
- Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis (when used with appropriate antituberculous chemotherapy), idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
- Rheumatic disorders: As adjunctive therapy for short-term administration during acute episodes or exacerbations in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis (including juvenile rheumatoid arthritis, with selected cases requiring low-dose maintenance). Also for dermatomyositis, polymyositis, and systemic lupus erythematosus.
- Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block (when used with appropriate antituberculous chemotherapy).
Dosage & Administration
Glucocorticoid dosage generally depends on the severity of the condition and patient response. For chronic conditions, the lowest effective dose should be used. Always consult a registered physician for medication use.
For Tablets:
- Adults: Daily oral dosages vary from 1 mg to 10 mg. Higher doses may be temporarily needed to control disease, then gradually decreased.
- Children: 0.03-0.20 mg/kg body weight, according to individual response.
- Dexamethasone suppression test:
- Short test: 1 mg given at 11 p.m., plasma cortisol measured next morning.
- Longer test: 0.5 mg every 6 hours for 48 hours, followed by 2 mg every 6 hours for another 48 hours. 24-hour urine collections for 17 alpha-hydroxycorticoids before, during, and at the end of the test.
For Injection (IV, IM, or Local Injection):
- Systemic therapy (Adults): Daily doses of 0.05-0.20 mg/kg body weight are usually sufficient.
- Emergencies (e.g., anaphylaxis, acute severe asthma, cerebral edema): Substantially higher doses are required. An initial dose of 10-20 mg IV is followed by 6 mg IV or IM every 6 hours until a satisfactory result, then gradually tapered.
- Administration Notes:
- Intravenous injections of massive doses should be given slowly over several minutes.
- Intramuscular administration should be deep IM to prevent subcutaneous atrophy.
- Intra-articular injections must be given under strictly aseptic conditions as glucocorticoids decrease infection resistance.
- Can be diluted with infusion fluids (Sodium chloride 0.9%, Anhydrous glucose 5%, Invert sugar 10%, Sorbitol 5%, Ringer's solution, Hartman's solution) and remains potent for at least 24 hours at room temperature and daylight.
- Local Therapy (Recommended doses):
- Intra-articularly: 2-4 mg in large joints, 0.8-1 mg in small joints.
- Intrabursally: 2-4 mg.
- In tendon sheaths: 0.4-1 mg.
- Frequency: May vary from every 3-5 days to every 2-3 weeks.
Important Considerations & Warnings
It is crucial to discuss your full medical history with your doctor before taking Dexamethasone.
Contraindications:
- Gastric and duodenal ulcers.
- Systemic and ophthalmic fungal infections.
- Viral infections: e.g., varicella (chickenpox) and herpes genitalis infections. Viral infections of the eye.
- Glaucoma.
- Hypersensitivity to corticosteroids.
Side Effects (associated with prolonged systemic therapy):
- Endocrine and metabolic: Cushing-like syndrome, hirsutism, menstrual irregularities, premature epiphyseal closure, secondary adrenocortical and pituitary unresponsiveness, decreased glucose tolerance, negative nitrogen and calcium balance.
- Fluid and electrolyte: Sodium and fluid retention, hypertension, potassium loss, hypokalemic alkalosis.
- Musculoskeletal: Myopathy (muscle weakness), abdominal distension, osteoporosis, aseptic necrosis of femoral and humeral heads.
- Gastrointestinal: Gastric and duodenal ulceration, perforation, and hemorrhage.
- Dermatological: Impaired wound healing, skin atrophy, striae (stretch marks), petechiae and ecchymoses (bruising), facial erythema (redness), increased sweating, acne.
- Central Nervous System: Psychic disturbances (euphoria to frank psychotic manifestations), convulsions; in children, pseudotumor cerebri (benign intracranial hypertension) with vomiting and papilledema.
- Ophthalmic: Glaucoma, increased intraocular pressure, posterior subcapsular cataracts.
- Immunosuppressive: Increased susceptibility to infections, decreased responsiveness to vaccination and skin tests.
Pregnancy & Lactation:
- Pregnancy Category C.
- There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
- Lactation: Glucocorticoids appear in breast milk. Mothers taking high dosages of corticosteroids should be advised not to breastfeed.
Precautions & Warnings:
- General: Use the lowest possible dose to control the condition; reduction should be gradual.
- Cardio-renal: Use with caution in patients with congestive heart failure, hypertension, or renal insufficiency.
- Endocrine: Drug-induced secondary adrenocortical insufficiency can be minimized by gradual dosage reduction.
- Gastrointestinal: Use with caution in active or latent peptic ulcers, diverticulitis, intestinal anastomoses, and nonspecific ulcerative colitis, as steroids may increase the risk of perforation.
- Musculoskeletal: Special consideration for patients at increased risk of osteoporosis (e.g., postmenopausal women) before starting therapy.
- Neuro-psychiatric: Acute myopathy observed with high doses, especially in myasthenia gravis or with neuromuscular blocking drugs. Psychic derangements can occur, ranging from euphoria to frank psychotic manifestations.
Drug Interactions:
- Diuretics and/or cardiac glycosides: Enhanced potassium loss, increasing toxicity of cardiac glycosides (due to hypokalemia).
- Antidiabetics: Glucocorticoids may impair glucose tolerance, increasing the need for antidiabetic drugs.
- Non-steroidal anti-inflammatory drugs (NSAIDs): Increased incidence and/or severity of gastrointestinal ulceration.
- Oral anti-coagulants: Glucocorticoids may alter the need for these drugs.
- Liver enzyme-inducing drugs (e.g., rifampicin, ephedrine, barbiturates, phenytoin, primidone): Glucocorticoids may be less effective.
- Salicylates: If patients on long-term glucocorticoid therapy also take salicylates, any reduction in glucocorticoid dosage should be cautious, as salicylate intoxication has been reported.
- Antacids (especially magnesium trisilicate): May impair gastrointestinal absorption of glucocorticoids. Space doses as far apart as possible.
Use in Special Populations:
- Pediatric patients: Should be titrated to the lowest effective dose to minimize potential growth effects.
Overdose Effects
- Overdosage is unlikely.
- Treatment for overdosage is supportive and symptomatic therapy.
Storage Conditions
Comment